-61%

est. 2Y upside i

HealthcareSeries B

Rank

#2530

Sector

Biotechnology

Est. Liquidity

~2Y

Data Quality

Data: High

BreezeBio (formerly GenEdit) operates in the high-growth genetic medicine delivery market with a strong proprietary NanoGalaxy platform, addressing a critical industry challenge.

Last updated: March 10, 2026

Bull (27%)+200%

BreezeBio's NanoGalaxy platform achieves significant clinical milestones for its internal therapeutic programs and secures additional major partnerships, validating its non-viral delivery technology. This drives revenue growth to over $50M by 2028 and justifies a valuation of nearly $500M, representing a 3x increase from the current valuation.

Base (28%)+30%

The company makes steady progress with its existing collaborations and advances some pipeline candidates, but faces typical biotech development delays and moderate competitive pressure. Revenue grows to $10-15M by 2028, leading to an IPO or acquisition at a valuation of approximately $215M, a modest increase from current levels.

Bear (45%)-60%

Clinical trials encounter significant setbacks, or major incumbents develop highly effective competing delivery methods, eroding BreezeBio's competitive advantage. The high capital intensity leads to a challenging fundraising environment, resulting in a down round or acquisition at a valuation of approximately $66M, wiping out most common-stock value given the substantial liquidation preferences.

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

72%

Investors hold $120M in liquidation preferences. In an exit at or below $120M, common stock holders would receive little to no value. At the current $166M valuation, common stock holders would only share in the $46M above the preference stack.

Dilution Risk

high

As a capital-intensive biotech company with $2M revenue, BreezeBio will likely require additional funding rounds before an IPO, leading to further dilution for existing equity holders.

Secondary Liquidity

limited

The current valuation is based on a secondary market, indicating some liquidity exists, but it is likely limited for employees and not a consistently active market.

Questions to Ask at the Interview

Strategic questions based on GenEdit's data — designed to show you've done your homework.

  • 1

    “Given the 'medium' incumbent threat and your 'strong' competitive moat with the NanoGalaxy platform, how do you foresee major gene editing companies like CRISPR Therapeutics and Intellia Therapeutics evolving their own delivery capabilities, and what is BreezeBio's strategy to maintain its specialized advantage?”

  • 2

    “With current revenue at ~$2M and a TAM of $22.8B, what are the key milestones and revenue growth targets BreezeBio aims to achieve over the next 2-3 years to justify its current valuation and prepare for a potential IPO?”

  • 3

    “Considering the recent pre-IPO financing round and the significant preference stack from $120M in total funding, what is the company's anticipated timeline for a liquidity event, and how does BreezeBio plan to ensure meaningful returns for common stock holders?”

Community

Valuation Sentiment

Our model estimates -61% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.